OASIS clinical study

Ulcerative Colitis Adults Clinical Study

ROCKVILLE, Md., Jan. 12, 2016 /PRNewswire-USNewswire/ — Ulcerative Colitis (UC) is a chronic disease of the colon that causes the colon to become inflamed and forms ulcers. UC is a type of irritable bowel disease (IBD), which is a term that describes conditions with chronic or recurring inflammation of the gastrointestinal tract.

The number of patients diagnosed with IBD has increased significantly across the past 50 years, with 1.6 million people in the United States alone affected by IBD. The incidence of IBDs, including UC, is highest among people between the ages of 20 and 40, often affecting individuals during their healthiest and most productive years of life.

Managing the symptoms of UC is a constant challenge for patients with frequent bathroom trips, abdominal cramps, and diarrhea significantly affecting the day-to-day routines of people with the disease. The availability of an oral medication such as the one being studied in the OASIS clinical study could offer patients an additional, more convenient treatment for UC.

The OASIS clinical study is evaluating an investigational medication to learn if it may safely and effectively reduce the inflammation of the gut in patients with moderately to severely active UC. The medication is considered investigational because it is not approved by health authorities, including the U.S. Food and Drug Administration (FDA), for the treatment of UC.

Clinical studies are done to help determine if investigational medications are safe and are effective in treating diseases and conditions. People volunteer to participate in clinical studies and these studies play an important role in the development of medications. Many drugs, therapies, and devices that are used today are the result of past clinical studies.

The study is being conducted at more than 100 clinical centers worldwide, and about 240 adults aged 18 to 80 will participate in the OASIS clinical study. The study will last about 16 to 18 weeks and include 7 to 10 visits to the study clinic.

To learn more about the OASIS study, visit



Success of anti-TNF Therapy for IBD May Depend on Serum Level

A retrospective study in Clinical Gastroenterology and Hepatology suggests a significant association between serum levels of anti-tumor necrosis factor (TNF) agents and the level of mucosal healing for patients with inflammatory bowel disease (IBD).

Since anti-TNF agents were developed, their use in the treatment of IBD has evolved significantly. While the medications work well for many patients, there is a subgroup of IBD sufferers who fail to respond or who lose response to these otherwise very effective drugs. Even for those patients who do respond, it is not yet well known at what level of treatment anti-TNF medications should be delivered. The issue is of clinical importance, because while the anti-TNFs are generally well-tolerated, cytokine manipulation also has potentially deleterious consequences.

In the current review, the researchers performed a retrospective cross-sectional study of 145 patients with IBD treated with infliximab (n=78) or adalimumab (n=67) at a medical center in Israel from 2009 through 2014. They collected data from colonoscopy examinations.

Mucosal healing was defined as simple endoscopic score of

See more at: Success of anti-TNF therapy for IBD May Depend on Serum Level

Omaha Medical Groups

Omaha Medical Groups Join Together

Two Omaha medical groups have joined forces to combat Crohn’s disease and ulcerative colitis.

Midwest Gastrointestinal Associates, PC, (MGI), and Colon and Rectal Surgery, Inc. announced Tuesday plans to open Nebraska’s only clinically integrated facility dedicated to the diagnosis and treatment of inflammatory bowel diseases (IBD). The center will be called The Nebraska Crohn’s and Colitis Center of Excellence.

Officials with the center say they hope to utilize an evidence-based, collaborative approach between gastroenterologists, colorectal surgeons, nutritionists, case managers and pathologists for the comprehensive care of patients with IBD.

IBD encompasses a group of disorders which affect the intestine causing chronic inflammatory changes and result in abdominal pain, diarrhea, loss of appetite and multiple other symptoms.

Crohn’s disease and ulcerative colitis are the most common IBD conditions. The cause of inflammatory bowel disease remains unknown.

The Nebraska Crohn’s and Colitis Center of Excellence will be located near 90th and Dodge.

Read More: Omaha Medical Groups Join Together